Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, Jubb AM, Serio AW, Krause KM, Daikos GL; CARE Study Group.

N Engl J Med. 2019 Feb 21;380(8):791-793. doi: 10.1056/NEJMc1807634. No abstract available.

PMID:
30786196
2.

Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial.

File TM Jr, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, Seltzer E, Paukner S, Wicha WW, Talbot GH, Gasink LB.

Clin Infect Dis. 2019 Feb 4. doi: 10.1093/cid/ciz090. [Epub ahead of print]

PMID:
30722059
3.

Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future HABP/VABP clinical trials.

Weiss E, Zahar JR, Alder J, Asehnoune K, Bassetti M, Bonten MJM, Chastre J, De Waele J, Dimopoulos G, Eggimann P, Engelhardt M, Ewig S, Kollef M, Lipman J, Luna C, Martin-Loeches I, Pagani L, Palmer LB, Papazian L, Poulakou G, Prokocimer P, Rello J, Rex JH, Shorr AF, Talbot GH, Thamlikitkul V, Torres A, Wunderink RG, Timsit JF.

Clin Infect Dis. 2019 Feb 4. doi: 10.1093/cid/ciz093. [Epub ahead of print]

PMID:
30722013
4.

The Infectious Diseases Society of America's 10 × '20 Initiative (Ten New Systemic Antibacterial Agents FDA-approved by 2020): Is 20 × '20 a Possibility?

Talbot GH, Jezek A, Murray BE, Jones RN, Ebright RH, Nau GJ, Rodvold KA, Newland JG, Boucher HW; Infectious Diseases Society of America.

Clin Infect Dis. 2019 Feb 1. doi: 10.1093/cid/ciz089. [Epub ahead of print]

PMID:
30715222
5.

Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.

Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH.

Lancet Infect Dis. 2019 Mar;19(3):265-274. doi: 10.1016/S1473-3099(18)30614-5. Epub 2019 Jan 29.

PMID:
30709665
6.

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.

Talbot GH, Das A, Cush S, Dane A, Wible M, Echols R, Torres A, Cammarata S, Rex JH, Powers JH, Fleming T, Loutit J, Hoffmann S; Foundation for the National Institutes of Health Biomarkers Consortium HABP/VABP Project Team.

J Infect Dis. 2019 Jan 11. doi: 10.1093/infdis/jiy578. [Epub ahead of print]

PMID:
30649434
7.
8.

The CDI-DaySyms: Content Development of a New Patient-Reported Outcome Questionnaire for Symptoms of Clostridium difficile Infection.

Kleinman L, Talbot GH, Hunsche E, Schüler R, Nord CE.

Value Health. 2018 Apr;21(4):441-448. doi: 10.1016/j.jval.2017.08.3017. Epub 2017 Nov 7. Review.

PMID:
29680101
9.

Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.

Rex JH, Talbot GH, Goldberger MJ, Eisenstein BI, Echols RM, Tomayko JF, Dudley MN, Dane A.

Clin Infect Dis. 2017 Jul 1;65(1):141-146. doi: 10.1093/cid/cix246. Review.

10.

Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.

File TM Jr, Eckburg PB, Talbot GH, Llorens L, Friedland HD.

Int J Antimicrob Agents. 2017 Aug;50(2):247-251. doi: 10.1016/j.ijantimicag.2017.01.043. Epub 2017 Jun 6.

PMID:
28599867
11.

The Fight Against Multidrug-Resistant Bacteria.

Boucher HW, Cosgrove SE, Cox E, Talbot GH.

Ann Intern Med. 2017 Jan 3;166(1):78-79. doi: 10.7326/L16-0584. No abstract available.

PMID:
28030674
12.

The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?

Talbot GH.

Clin Infect Dis. 2017 Jan 15;64(2):218-220. doi: 10.1093/cid/ciw752. Epub 2016 Dec 21. No abstract available.

PMID:
28003217
13.

In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.

Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4407-11. doi: 10.1128/AAC.00627-16. Print 2016 Jul.

14.

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.

Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S.

Drug Saf. 2016 Feb;39(2):147-57. doi: 10.1007/s40264-015-0374-9. Review.

15.

Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health.

Talbot GH, Powers JH, Hoffmann SC; Biomarkers Consortium of the Foundation for the National Institutes of Health CABP-ABSSSI and HABP-VABP Project Teams.

Clin Infect Dis. 2016 Mar 1;62(5):603-7. doi: 10.1093/cid/civ927. Epub 2015 Dec 13.

16.

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.

Gerding DN, Hecht DW, Louie T, Nord CE, Talbot GH, Cornely OA, Buitrago M, Best E, Sambol S, Osmolski JR, Kracker H, Locher HH, Charef P, Wilcox M.

J Antimicrob Chemother. 2016 Jan;71(1):213-9. doi: 10.1093/jac/dkv300. Epub 2015 Oct 3.

17.

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.

Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, Cornely OA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6266-73. doi: 10.1128/AAC.00504-15. Epub 2015 Jul 27.

18.

Cdad-Daysyms™: A New Patient-Reported Outcome Tool For Clostridium Difficile-Associated Diarrhoea.

Kleinman L, Talbot GH, Schüler R, Broderick K, Revicki D, Nord CE.

Value Health. 2014 Nov;17(7):A569. doi: 10.1016/j.jval.2014.08.1897. Epub 2014 Oct 26. No abstract available.

19.

Dalbavancin or oritavancin for skin infections.

Boucher HW, Talbot GH, Dunne MW.

N Engl J Med. 2014 Sep 18;371(12):1161-2. doi: 10.1056/NEJMc1407925. No abstract available.

PMID:
25229922
20.

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW.

N Engl J Med. 2014 Jun 5;370(23):2169-79. doi: 10.1056/NEJMoa1310480.

21.

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D; Infectious Diseases Society of America.

Clin Infect Dis. 2013 Jun;56(12):1685-94. doi: 10.1093/cid/cit152. Epub 2013 Apr 17.

22.

Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.

Prince WT, Ivezic-Schoenfeld Z, Lell C, Tack KJ, Novak R, Obermayr F, Talbot GH.

Antimicrob Agents Chemother. 2013 May;57(5):2087-94. doi: 10.1128/AAC.02106-12. Epub 2013 Feb 19.

23.

β-Lactam antimicrobials: what have you done for me lately?

Talbot GH.

Ann N Y Acad Sci. 2013 Jan;1277:76-83. doi: 10.1111/j.1749-6632.2012.06809.x. Epub 2012 Nov 29. Review.

PMID:
23346858
24.

Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan.

Talbot GH.

Mayo Clin Proc. 2012 Dec;87(12):1231-2; author reply 1232. doi: 10.1016/j.mayocp.2012.09.011. No abstract available.

25.

Prospective study of the Wilson severity-of-illness scoring system for complicated skin and skin structure infections.

Talbot GH, O'Neal T, Das AF, Thye D.

Antimicrob Agents Chemother. 2013 Jan;57(1):647-50. doi: 10.1128/AAC.01344-12. Epub 2012 Nov 5.

26.
27.

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 2 investigators.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097.

PMID:
21482568
28.

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 1 investigators.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii19-32. doi: 10.1093/jac/dkr096.

PMID:
21482566
29.

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 2 investigators.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv53-iv65. doi: 10.1093/jac/dkq255.

PMID:
21115455
30.

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv41-51. doi: 10.1093/jac/dkq254.

PMID:
21115454
31.

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.

File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D.

Clin Infect Dis. 2010 Dec 15;51(12):1395-405. doi: 10.1086/657313. Epub 2010 Nov 10. Erratum in: Clin Infect Dis. 2011 Apr 1;52(7):967.

PMID:
21067350
32.

The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes.

Talbot GH.

Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S55-8. doi: 10.1086/655988. Review.

PMID:
20929372
33.

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D.

Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827.

PMID:
20695801
34.
35.

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

Ge Y, Whitehouse MJ, Friedland I, Talbot GH.

Antimicrob Agents Chemother. 2010 Aug;54(8):3427-31. doi: 10.1128/AAC.01753-09. Epub 2010 May 10.

36.

Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.

Spellberg B, Talbot GH, Boucher HW, Bradley JS, Gilbert D, Scheld WM, Edwards J Jr, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Clin Infect Dis. 2009 Aug 1;49(3):383-91. doi: 10.1086/600296. Review.

37.

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J.

Clin Infect Dis. 2009 Jan 1;48(1):1-12. doi: 10.1086/595011. Review.

PMID:
19035777
38.

Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Spellberg B, Talbot GH, Brass EP, Bradley JS, Boucher HW, Gilbert DN; Infectious Diseases Society of America.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S249-65. Review. No abstract available.

39.

Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients?

Talbot GH.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S180-5. doi: 10.1086/591401. Review.

PMID:
18986286
40.

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.

Ge Y, Biek D, Talbot GH, Sahm DF.

Antimicrob Agents Chemother. 2008 Sep;52(9):3398-407. doi: 10.1128/AAC.00149-08. Epub 2008 Jul 14.

41.

What is in the pipeline for Gram-negative pathogens?

Talbot GH.

Expert Rev Anti Infect Ther. 2008 Feb;6(1):39-49. doi: 10.1586/14787210.6.1.39. Review.

PMID:
18251663
42.

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.

Talbot GH, Thye D, Das A, Ge Y.

Antimicrob Agents Chemother. 2007 Oct;51(10):3612-6. Epub 2007 Aug 6.

43.

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Clin Infect Dis. 2006 Mar 1;42(5):657-68. Epub 2005 Jan 25. Review. Erratum in: Clin Infect Dis. 2006 Apr 1;42(7):1065.

PMID:
16447111
45.

Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae.

Moellering RC Jr, Craig W, Edmond M, Farrell DJ, Ferraro MJ, File TM Jr, Klein J, Lonks J, Metlay JP, Sahm D, Talbot GH; Consensus Working Group.

J Chemother. 2002 Jul;14 Suppl 3:42-56. Review.

PMID:
12418560
46.

Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients.

Loeffler AM, Drew RH, Perfect JR, Grethe NI, Stephens JW, Gray SL, Talbot GH.

Pediatr Infect Dis J. 2002 Oct;21(10):950-6.

PMID:
12394819
47.

Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.

Linden PK, Moellering RC Jr, Wood CA, Rehm SJ, Flaherty J, Bompart F, Talbot GH; Synercid Emergency-Use Study Group.

Clin Infect Dis. 2001 Dec 1;33(11):1816-23. Epub 2001 Oct 19.

PMID:
11668430
48.

Rigid nasal endoscopy versus sinus puncture and aspiration for microbiologic documentation of acute bacterial maxillary sinusitis.

Talbot GH, Kennedy DW, Scheld WM, Granito K; Endoscopy Study Group.

Clin Infect Dis. 2001 Nov 15;33(10):1668-75. Epub 2001 Oct 5.

PMID:
11595989
49.
50.

Successful administration of quinupristin/dalfopristin in the outpatient setting.

Rehm SJ, Graham DR, Srinath L, Prokocimer P, Richard MP, Talbot GH.

J Antimicrob Chemother. 2001 May;47(5):639-45.

PMID:
11328776

Supplemental Content

Loading ...
Support Center